{"id":2533,"date":"2017-10-03T00:00:00","date_gmt":"2017-10-02T22:00:00","guid":{"rendered":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/"},"modified":"2019-01-13T16:38:22","modified_gmt":"2019-01-13T15:38:22","slug":"03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/","title":{"rendered":"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors"},"content":{"rendered":"<p><strong>New preclinical data in Cancer Immunology Research demonstrate that increasing tumor-infiltrating T cells through inhibition of CXCL12 by NOX-A12 synergizes with PD-1 checkpoint inhibition<\/strong><\/p>\n<p>Berlin, Germany, October 03, 2017 &#8211; NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the publication of novel preclinical data for NOXXON\u2019s lead cancer compound, NOX-A12 (olaptesed pegol). The results highlighted the effects of NOX-A12 in vitro and in an animal model, emphasizing NOX-A12\u2019s ability to enhance the infiltration of T and NK immune cells into tumor tissue thereby synergizing with and overcoming resistance to PD-1 checkpoint inhibition with the goal of enabling the destruction of cancer. Building on extensive clinical experience and safety data, the lead program NOX-A12 will deliver top-line data from a Keytruda\u00ae combination trial in metastatic colorectal and pancreatic cancer patients in 2018.<\/p>\n<p>\u201cImmune checkpoint inhibitors promote T cell-mediated killing of cancer cells and induce striking responses. However, as only a subset of patients benefits from such treatment, novel strategies to enhance the effect are needed. Although preclinical, we believe that the results of this study further validate the potential of NOX-A12 as a combination therapy to improve outcomes in multiple oncology indications,\u201d said Aram Mangasarian, CEO of NOXXON. \u201cThe goal of our current clinical trial is to reproduce these results and to deliver a meaningful therapeutic impact in colorectal and pancreatic cancer patients.\u201d<\/p>\n<p>The pre-clinical study titled \u201cIncreasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade\u201d aimed to evaluate the potential of NOX-A12 as a combination therapy approach to improve checkpoint inhibition therapies. In particular, the study investigated whether NOX-A12-based inhibition of the chemokine CXCL12, a key factor in TME-driven immune suppression, would increase lymphocyte infiltration into the tumor and thus enable effective killing of cancer cells in combination with checkpoint inhibitors. By employing three-dimensional cell culture models that mimic a solid tumor with a CXCL12-abundant TME, it was demonstrated that NOX-A12 enhanced the infiltration of T and NK cells in a dose-dependent manner. NOX-A12 and PD-1 checkpoint inhibition synergistically enhanced T cell activation in the model indicating that both agents complement each other. The findings were subsequently validated in vivo in a murine model of colorectal cancer where the addition of NOX-A12 significantly improved anti-PD-1 therapy. Taken together, the results demonstrate that CXCL12 inhibition can break the immune-privilege of the TME by paving the way for immune effector cells into the tumor and that NOX-A12 could be an important therapeutic approach to broadening the applicability of checkpoint inhibitors in cancer patients.<\/p>\n<p>The results, published in the current issue of Cancer Immunology Research can be accessed through the current online version of the journal and the following link: <br \/><a href=\"http:\/\/cancerimmunolres.aacrjournals.org\/cgi\/content\/abstract\/2326-6066.CIR-16-0303\">http:\/\/cancerimmunolres.aacrjournals.org\/cgi\/content\/abstract\/2326-6066.CIR-16-0303<\/a><\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2533\" data-postid=\"2533\" class=\"themify_builder_content themify_builder_content-2533 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->","protected":false},"excerpt":{"rendered":"<p>New preclinical data in Cancer Immunology Research demonstrate that increasing tumor-infiltrating T cells through inhibition of CXCL12 by NOX-A12 synergizes with PD-1 checkpoint inhibition<\/p>\n","protected":false},"author":1,"featured_media":2607,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"New preclinical data in Cancer Immunology Research demonstrate that increasing tumor-infiltrating T cells through inhibition of CXCL12 by NOX-A12 synergizes with PD-1 checkpoint inhibition\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2017-10-02T22:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-13T15:38:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"norman.krey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"norman.krey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/\"},\"author\":{\"name\":\"norman.krey\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\"},\"headline\":\"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors\",\"datePublished\":\"2017-10-02T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:38:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/\"},\"wordCount\":483,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/\",\"url\":\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/\",\"name\":\"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2017-10-02T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:38:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\",\"name\":\"norman.krey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"caption\":\"norman.krey\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"New preclinical data in Cancer Immunology Research demonstrate that increasing tumor-infiltrating T cells through inhibition of CXCL12 by NOX-A12 synergizes with PD-1 checkpoint inhibition","og_url":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2017-10-02T22:00:00+00:00","article_modified_time":"2019-01-13T15:38:22+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png","type":"image\/png"}],"author":"norman.krey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"norman.krey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/"},"author":{"name":"norman.krey","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b"},"headline":"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors","datePublished":"2017-10-02T22:00:00+00:00","dateModified":"2019-01-13T15:38:22+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/"},"wordCount":483,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/","url":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/","name":"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2017-10-02T22:00:00+00:00","dateModified":"2019-01-13T15:38:22+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/03-10-17-noxxon-publishes-preclinical-proof-of-concept-data-for-lead-product-nox-a12-in-combination-with-checkpoint-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b","name":"norman.krey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","caption":"norman.krey"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2533"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2533"}],"version-history":[{"count":3,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2533\/revisions"}],"predecessor-version":[{"id":2644,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2533\/revisions\/2644"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media\/2607"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}